In December 2015, the National Minority Quality Forum (NMQF), assisted by the Diabetes Translational Research Center, published a comprehensive analysis of the inherent limitations of CMS' methodology (6). According to the report, investigators determined that the study design used by CMS was flawed. Because CMS failed to establish baseline values for acquisition behaviors and health status, it was impossible to determine whether changes in either acquisition behaviors or health outcomes actually occurred during establishment of their metrics. Additionally, the agency failed to construct a matched control group, which would have enabled CMS to determine whether competitive bidding was an independent contributor to any changes detected, and the significance of those changes, compared with beneficiaries not included in the nine test markets. There was also a lack of transparency in describing their methodology and reporting their findings.
One major unanswered question is why these signals were not recognized by CMS. We know that Medicare beneficiaries treated with insulin or other insulinotropic medications are at significantly higher risk of hypoglycemia (7, 8) . SMBG is a critical component of preventing hypoglycemia. If competitive bidding is disrupting beneficiary access to needed SMBG supplies, then it may follow that one may see increased adverse events, such as hypoglycemia, perhaps leading to an increase in morbidity and mortality. Thus, the resulting implications may well continue to increase the cost of diabetes care. Thus, it is imperative that the findings from the study by Puckrein et al. (3) be considered, evaluated, and addressed by CMS.
